Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
WALTHAM, Mass., Feb. 02, 2016 -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2015 financial results on Thursday, February 25, 2016.
In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 7:30 a.m. ET on Thursday, February 25, 2016 to discuss the results.
Conference Call Information:
Date: Thursday, February 25, 2016
Time: 7:30 a.m. ET
Domestic Dial-in Number: 1-877-705-6003
International Dial-in Number: 1-201-493-6725
Live webcast: http://public.viavid.com/player/index.php?id=118001
For those unable to participate in the conference call or webcast, a replay will be available beginning February 25, 2016 at 10:30 a.m. ET until March 10, 2016 at 11:59 p.m. ET. To access the replay, dial 1-877-870-5176 or 1-858-384-5517. The replay pin number is 13629094.
A live audio webcast of the call will also be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for 14 days on the Radius website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company's website.
About Radius
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential applications in oncology. For more information, please visit www.radiuspharm.com.
CONTACT: Investor Relations Barbara Ryan 203-274-2825 [email protected] Media Alice Pomponio V.P. Corporate Affairs 617-551-4099 [email protected]
